Solid Biosciences Inc. - Common Stock, $0.001 par value per share (SLDB)
CUSIP: 83422E204
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, $0.001 par value per share
- Shares outstanding
- 92,783,558
- Total 13F shares
- 82,208,819
- Share change
- +3,372,202
- Total reported value
- $400,360,815
- Put/Call ratio
- 23%
- Price per share
- $4.87
- Number of holders
- 110
- Value change
- +$32,116,218
- Number of buys
- 75
- Number of sells
- 47
Quarterly Holders Quick Answers
What is CUSIP 83422E204?
CUSIP 83422E204 identifies SLDB - Solid Biosciences Inc. - Common Stock, $0.001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 83422E204:
Top shareholders of SLDB - Solid Biosciences Inc. - Common Stock, $0.001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
3/4/5
13F
|
10%+ Owner · Company |
8.5%
from 13F
|
11,478,752
mixed-class rows
|
$46,252,926 | — | 19 Feb 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
13%
|
11,906,646
|
$44,054,590 | — | 31 Mar 2025 | |
| Adage Capital Management, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,248,084
|
$32,115,515 | — | 18 Feb 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
8%
|
7,415,905
|
$27,438,849 | — | 31 Mar 2025 | |
| Invus Global Management, LLC |
13D/G
|
Raymond Debbane |
9.6%
|
7,415,905
|
$27,216,371 | +$13,457,391 | 31 Mar 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
7.3%
|
6,729,484
|
$24,899,091 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13D/G
13F
|
Company |
6.1%
|
4,712,573
|
$22,954,472 | $0 | 30 Jun 2025 | |
| Adam Koppel |
3/4/5
|
Director, 10%+ Owner |
—
mixed-class rows
|
4,044,232
mixed-class rows
|
$22,311,238 | — | 11 Jan 2024 | |
| Commodore Capital LP |
13F
|
Company |
6.3%
|
5,825,000
|
$21,552,500 | — | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
3/4/5
|
Company · 10%+ Owner |
4.7%
|
4,330,446
|
$16,022,650 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
3.8%
|
3,517,888
|
$13,016,186 | — | 31 Mar 2025 | |
| VR Adviser, LLC |
13F
|
Company |
2.7%
|
2,481,400
|
$9,181,180 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.7%
|
2,460,450
|
$9,103,665 | — | 31 Mar 2025 | |
| Redmile Group, LLC |
13F
|
Company |
2.2%
|
2,019,171
|
$7,470,933 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2%
|
1,885,883
|
$6,977,767 | — | 31 Mar 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
1.9%
|
1,753,558
|
$6,488,165 | — | 31 Mar 2025 | |
| Monashee Investment Management LLC |
13F
|
Company |
1.8%
|
1,673,412
|
$6,191,624 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.8%
|
1,642,356
|
$6,076,717 | — | 31 Mar 2025 | |
| Alyeska Investment Group, L.P. |
13F
|
Company |
1.8%
|
1,640,821
|
$6,071,038 | — | 31 Mar 2025 | |
| BCLS II Equity Opportunities GP, LLC |
3/4/5
|
Director, 10%+ Owner |
—
class O/S missing
|
904,160
|
$5,000,005 | — | 11 Jan 2024 | |
| Boxer Capital Management, LLC |
13F
|
Company |
1.3%
|
1,240,700
|
$4,590,590 | — | 31 Mar 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
1.3%
|
1,240,700
|
$4,590,590 | — | 31 Mar 2025 | |
| Finepoint Capital LP |
13F
|
Company |
1%
|
961,251
|
$3,556,629 | — | 31 Mar 2025 | |
| Casdin Capital, LLC |
13F
|
Company |
0.84%
|
775,000
|
$2,867,500 | — | 31 Mar 2025 | |
| EcoR1 Capital, LLC |
13F
|
Company |
0.8%
|
744,450
|
$2,754,465 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.68%
|
631,823
|
$2,337,745 | — | 31 Mar 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.68%
|
627,274
|
$2,320,914 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.58%
|
534,564
|
$1,977,887 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.57%
|
530,859
|
$1,964,595 | — | 31 Mar 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.49%
|
452,239
|
$1,673,284 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.47%
|
436,276
|
$1,614,221 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.38%
|
353,722
|
$1,308,774 | — | 31 Mar 2025 | |
| Joel Solomon Zev Schneider |
3/4/5
|
Chief Operating Officer |
—
class O/S missing
|
236,270
|
$1,306,573 | — | 14 Mar 2022 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.36%
|
336,325
|
$1,244,404 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.3%
|
281,368
|
$1,041,062 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.29%
|
269,481
|
$998,181 | — | 31 Mar 2025 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.25%
|
230,000
|
$851,001 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.22%
|
201,419
|
$745,250 | — | 31 Mar 2025 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.21%
|
198,150
|
$733,155 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.21%
|
197,788
|
$731,816 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.19%
|
180,137
|
$666,507 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.19%
|
177,898
|
$658,223 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.19%
|
175,400
|
$648,980 | — | 31 Mar 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.18%
|
167,031
|
$618,015 | — | 31 Mar 2025 | |
| Resolute Capital Asset Partners LLC |
13F
|
Company |
0.16%
|
150,000
|
$555,000 | — | 31 Mar 2025 | |
| SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC |
13F
|
Company |
0.15%
|
141,552
|
$523,742 | — | 31 Mar 2025 | |
| David M. Knott Jr. |
13F
|
Individual |
0.14%
|
132,000
|
$488,400 | — | 31 Mar 2025 | |
| Birchview Capital, LP |
13F
|
Company |
0.14%
|
128,768
|
$476,442 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.12%
|
114,695
|
$424,372 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.12%
|
113,099
|
$418,468 | — | 31 Mar 2025 |
Institutional Holders of Solid Biosciences Inc. - Common Stock, $0.001 par value per share (SLDB) as of Q2 2025
As of 30 Jun 2025,
Solid Biosciences Inc. - Common Stock, $0.001 par value per share (SLDB) was held by
110 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
82,208,819 shares.
The largest 10 holders included
PERCEPTIVE ADVISORS LLC, Bain Capital Life Sciences Investors, LLC, Siren, L.L.C., ADAGE CAPITAL PARTNERS GP, L.L.C., RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc., VANGUARD GROUP INC, FMR LLC, CITADEL ADVISORS LLC, and Monashee Investment Management LLC.
This page lists
110
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
121
Q2 2025 holders
110
Holder diff
-11
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.